Moxifloxacino Viatris (Moxifloxacin Hydrochloride)

Moxifloxacin is a broad‑spectrum antibacterial that targets Gram‑negative and Gram‑positive pathogens in respiratory and skin infections.

• Community‑acquired bacterial pneumonia: eradicates the causative organisms and improves clinical recovery.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting bacteria.
• Acute bacterial exacerbations of chronic bronchitis: shortens symptom duration and prevents complications.
• Skin and soft tissue infections: clears bacterial contamination and promotes wound healing.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By blocking these targets, the drug prevents bacterial DNA synthesis and transcription, leading to bactericidal activity against a wide range of Gram‑negative and Gram‑positive organisms.

Moxifloxacin may cause a range of adverse reactions, most of which are dose‑independent and related to its fluoroquinolone class.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensations.
• Rash: mild skin erythema.
• Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles, requiring immediate medical attention.
• QT interval prolongation: may precipitate cardiac arrhythmias.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.
• Peripheral neuropathy: persistent sensory deficits.
• Clostridioides difficile infection: severe colitis.
• Hepatotoxicity: marked liver injury with jaundice.

Before prescribing Moxifloxacin, clinicians should evaluate patient history and potential risk factors.

• Contraindication: known hypersensitivity to fluoroquinolones or any component of the product.
• Cardiac risk: avoid in patients with a history of QT prolongation or taking other QT‑prolonging agents.
• Tendon health: advise patients with recent corticosteroid use or elderly patients about tendon injury risk.
• Renal/hepatic impairment: adjust monitoring in patients with severe organ dysfunction.
• Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Moxifloxacin can affect the pharmacokinetics or pharmacodynamics of several co‑administered drugs.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: markedly reduce absorption of moxifloxacin.
• Warfarin: may increase INR and bleeding risk.
• Cyclosporine: increased serum levels leading to nephrotoxicity.
• Theophylline: heightened risk of seizures.
• QT‑prolonging drugs (e.g., quinidine, haloperidol): additive cardiac conduction delay.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation.
• Corticosteroids: potential for tendon toxicity.
• Oral contraceptives: possible reduction in contraceptive efficacy.
• Diabetes medications: altered glucose control.
• Rifampin: may decrease moxifloxacin plasma concentrations.